Ballicules.com

Pancrelipase

CREON

Pronunciation: pan-kre-LI-pays

Pancrelipase ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Pancrelipase ballicule

What it isPorcine pancreatic enzyme replacement; exocrine pancreatic insufficiency.

Why this oneIt restores fat and protein digestion in cystic fibrosis, chronic pancreatitis and after pancreatectomy.

What limits itIt must be taken WITH food and not crushed, and acid destroys unprotected enzyme. Fibrosing colonopathy at very high doses in children.

Pancrelipase molecular structure (skeletal formula)
Molecular structure: Pancrelipase

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Exocrine pancreatic insufficiencyAdults & children ≥4 yr500 units/kg/meal (500–1,000 for chronic pancreatitis/pancreatectomy)titrate to 2,500 units/kg/meal2,500 units/kg/meal (≤10,000 units/kg/day; ≤4,000 units/g fat/day)
Exocrine pancreatic insufficiencyChildren >12 mo–<4 yr1,000 units/kg/mealtitrate to 2,500 units/kg/meal2,500 units/kg/meal
Exocrine pancreatic insufficiencyInfants birth–12 mo3,000 units per 120 mL formula or per breastfeeding

Titration Changes may require an adjustment period of several days

Renal Undefined

Hepatic Undefined

Do not exceed 2,500 units/kg/meal, 10,000 units/kg/day, or 4,000 units/g fat/day without investigation

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy Minimally absorbed systemically; no drug-associated risk identified.

Lactation Minimally absorbed; not expected to result in clinically relevant infant exposure.

Cost

Pancrelipase (CREON)
Strength#/mogeneric $/unitCostPlus
3000 USP lipase unitsDR capper unitnot offered
6000 USP lipase unitsDR capper unitnot offered
12000 USP lipase unitsDR capper unitnot offered
24000 USP lipase unitsDR capper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Pancrelipase is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

NO BOXED WARNINGS

Principal riskEnteric coating must not be crushed, and it must be taken with every fat-containing meal

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Defining liabilityHigh-dose fibrosing colonopathy and porcine-protein hypersensitivity

Open Pancrelipase in the interactive console ↗